Medexus PharmaceuticalsMEDXF +3.96%58 Days Inventory is 258.98 as of Mar. 2026, which is 65% above its 10-year median of 157.25. GuruFocus rates MEDXF with a GF Score™ of 58/100 and a GF Value™ of $1.30 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 916 Drug Manufacturers companies, Medexus Pharmaceuticals ranks worse than 81.11% on this metric.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Medexus Pharmaceuticals's Inventory Turnover for the
three
months ended in Mar. 2026 was 0.35.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Medexus Pharmaceuticals's Inventory-to-Revenue for the
three
months ended in Mar. 2026 was 1.31.
Medexus Pharmaceuticals (OTCPK:MEDXF) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Medexus Pharmaceuticals's Inventory Turnover for the
three
months ended in Mar. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Medexus Pharmaceuticals's Inventory to Revenue for the
three
months ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Medexus Pharmaceuticals Days Inventory Related Terms
Medexus Pharmaceuticals Days Inventory Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Medexus Pharmaceuticals's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medexus Pharmaceuticals Days Inventory vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Medexus Pharmaceuticals's Days Inventory distribution charts can be found below:
* The bar in red indicates where Medexus Pharmaceuticals's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medexus Pharmaceuticals (MEDXF) has a Days Inventory of 258.98 as of Mar. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Medexus Pharmaceuticals and its competitors. This is 65% above median its historical median of 157.25. Over the past decade, Medexus Pharmaceuticals' Days Inventory has ranged from 104.80 to 285.30. According to the industry distribution chart, Medexus Pharmaceuticals ranks #743 out of 916 companies in the Drug Manufacturers industry, placing it in the top 81.1%.
Is Medexus Pharmaceuticals' Days Inventory too high?
Medexus Pharmaceuticals' current Days Inventory of 258.98 is 65% above median its 10-year median of 157.25. Over the past 10 years, this metric has ranged from a low of 104.80 to a high of 285.30. The Drug Manufacturers industry median Days Inventory is 164.43. Medexus Pharmaceuticals' value of 258.98 is 57.5% above this industry median. Based on the distribution chart, Medexus Pharmaceuticals ranks #743 out of 916 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Medexus Pharmaceuticals has a GF Score™ of 58/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Medexus Pharmaceuticals' Days Inventory compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Medexus Pharmaceuticals ranks #743 out of 916 companies for Days Inventory. This places Medexus Pharmaceuticals in the lower half of its industry. The industry median Days Inventory is 164.43. Medexus Pharmaceuticals' value of 258.98 is 57.5% above this benchmark. Historically, Medexus Pharmaceuticals' own Days Inventory has ranged from 104.80 to 285.30 over the past decade. While the company's 10-year median is 157.25 vs. the industry median of 164.43, Medexus Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Drug Manufacturers company?
The median Days Inventory among Drug Manufacturers companies is 164.43, based on 916 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medexus Pharmaceuticals's current Days Inventory of 258.98 is 57.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Medexus Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Days Inventory is 164.43 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medexus Pharmaceuticals's current Days Inventory is 258.98, which is 65% above median its own 10-year median of 157.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medexus Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Medexus Pharmaceuticals (MEDXF) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.30, compared to a current price of $3.62 — trading 178.5% above its estimated fair value. The current Days Inventory is 258.98, which is 65% above median its 10-year median of 157.25 and 57.5% above the Drug Manufacturers industry median of 164.43. Medexus Pharmaceuticals' overall GF Score™ is 58/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Medexus Pharmaceuticals (MEDXF), the current Days Inventory is 258.98 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medexus Pharmaceuticals (MEDXF) Overvalued in 2026?
Based on GuruFocus' analysis, Medexus Pharmaceuticals stock appears to be overvalued.
The current stock price of $3.62 is trading 178.5% above its estimated GF Value™ of $1.30.
GuruFocus considers Medexus Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for MEDXF:
Days Inventory: 258.98 (65% above median its 10-year median of 157.25)
GF Value™: $1.30 vs. price of $3.62 (178.5% above fair value)
Industry Position: 57.5% above the Drug Manufacturers median (#743 of 916)
No single metric tells the full story. See the MEDXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medexus Pharmaceuticals Inc is a specialty pharmaceutical company with a powerful North American commercial platform and a growing portfolio of inventive and rare disease treatment solutions. The company's focus is on the therapeutic areas of oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Medexus products are generally sold in North America to wholesalers, distributors, government agencies, healthcare facilities and specialty pharmacies.
58GF Score
Get the complete analysis for MEDXF
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEDXF has been successfully added to your 
